{"id":698454,"date":"2010-03-23T09:51:33","date_gmt":"2010-03-23T13:51:33","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=69848"},"modified":"2010-03-23T09:51:33","modified_gmt":"2010-03-23T13:51:33","slug":"alnylam-gets-20m-from-takeda","status":"publish","type":"post","link":"https:\/\/mereja.com\/index\/698454","title":{"rendered":"Alnylam Gets $20M From Takeda"},"content":{"rendered":"\n
Biotech<\/a>, RNA Interference<\/a>, deals<\/a><\/div>\n

\t\tLuke Timmerman wrote:<\/strong><\/p>\n

Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: ALNY<\/a>) said today<\/a> it has earned a $20 million milestone payment from Japan-based Takeda Pharmaceuticals for handing over certain RNA interference documents, materials and know-how. The payment is part of the partnership between the two companies, first formed in May 2008, which could be worth more than $1 billion over time. Alnylam is eligible to receive more milestones and royalties if Takeda translates the technology into RNAi products.<\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

\t \t\t

\n

\n\"\"<\/a>
\n<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Biotech, RNA Interference, deals Luke Timmerman wrote: Cambridge, MA-based Alnylam Pharmaceuticals (NASDAQ: ALNY) said today it has earned a $20 million milestone payment from Japan-based Takeda Pharmaceuticals for handing over certain RNA interference documents, materials and know-how. The payment is part of the partnership between the two companies, first formed in May 2008, which could […]<\/p>\n","protected":false},"author":843,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[4821],"tags":[],"class_list":["post-698454","post","type-post","status-publish","format-standard","hentry","category-news"],"jetpack_featured_media_url":"","jetpack_shortlink":"https:\/\/wp.me\/p9NivD-2VHo","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts\/698454","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/users\/843"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/comments?post=698454"}],"version-history":[{"count":0,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts\/698454\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/media?parent=698454"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/categories?post=698454"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/tags?post=698454"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}